ADVFN US – Market Content Editor

AC Immune (NASDAQ:ACIU) surged 25% on Thursday after announcing promising interim Phase 2 findings for its experimental Parkinson’s disease treatment, indicating the therapy may help slow the underlying progression of the disorder. The company’s investigational therapy, ACI-7104.056 — an active immunotherapy targeting alpha-synuclein — produced encouraging outcomes in the VacSYn study involving patients in the…

Geron Corporation (NASDAQ:GERN) said Thursday it will carry out a major restructuring effort that includes reducing its workforce by around one-third — a move that will impact roughly 260 employees at the biopharmaceutical firm. The overhaul is expected to be largely completed during the first quarter of 2026. Geron anticipates that its operating expenses for…

zSpace Inc. (NASDAQ:ZSPC) announced Thursday that it has wrapped up a major restructuring initiative that included substantial workforce reductions and operational adjustments across its U.S. business. The augmented reality education technology company said the changes will lower its run-rate operating expenses by more than 30%. The overhaul included what the company described as significant staff…

Rezolute, Inc. (NASDAQ:RZLT) saw its stock plunge 90% on Thursday after revealing that its Phase 3 sunRIZE trial of ersodetug in congenital hyperinsulinism (HI) patients failed to achieve its primary endpoint or its key secondary objectives. According to the company, the study recorded roughly a 45% reduction in hypoglycemia events at the highest dose tested…

Coherent Corp. (NYSE:COHR) dropped 1.8% on Thursday after Bain Capital put forward another sizable share sale, marking the private equity firm’s third attempt in just over a month to trim its position in the laser systems manufacturer. According to Bloomberg News, citing sources familiar with the deal, Goldman Sachs Group Inc. (NYSE:GS) is marketing 5…

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) climbed 5% after the company released promising early-stage safety data for CRB-913, its oral CB1 inverse agonist under development for obesity treatment. The Phase 1a trial showed that CRB-913 was well tolerated, with no serious adverse events reported across both single- and multiple-ascending-dose cohorts. Importantly, the study revealed early signs…

Ciena Corporation (NYSE:CIEN) jumped 8.2% in premarket trading on Thursday after delivering fiscal fourth-quarter results that comfortably topped Wall Street expectations, supported by accelerating demand from cloud customers and expanding opportunities tied to AI infrastructure. For the quarter ended November 1, the networking equipment maker posted adjusted earnings of $0.91 per share, surpassing analyst expectations…

Synopsys (NASDAQ:SNPS) traded slightly lower in U.S. premarket action on Thursday, easing back after a sharp after-hours jump, even as the company reported fourth-quarter numbers that topped analyst expectations and issued a bullish outlook for fiscal 2026. The engineering and chip design software specialist—whose tools help semiconductor manufacturers validate increasingly complex processors—has benefited significantly from…